NCT06771960 Association Between RVT and Prognosis After Neoadjuvant Targeted Therapy in EGFR NSCLC
| NCT ID | NCT06771960 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Guangdong Provincial People's Hospital |
| Condition | Lung Cancer (NSCLC) |
| Study Type | OBSERVATIONAL |
| Enrollment | 120 participants |
| Start Date | 2025-02-01 |
| Primary Completion | 2025-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 120 participants in total. It began in 2025-02-01 with a primary completion date of 2025-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
EGFR-mutated NSCLC is a distinct subtype that responds well to targeted therapies. Neoadjuvant targeted therapy aims to downstage tumors and improve surgical outcomes, but the prognostic role of residual viable tumor (RVT) remains unclear. This retrospective study examines the association between RVT and survival outcomes. The findings will further validate the importance of RVT as a surrogate.
Eligibility Criteria
Inclusion Criteria: * Age 18-80 years old; * Pathologically diagnosed EGFR-mutated non-small cell lung cancer (NSCLC); * Treated with neoadjuvant targeted therapy; * Undergoing definitive surgery. Exclusion Criteria: * A history of prior chemotherapy, immunotherapy, or radiotherapy. * A history of malignancy or lung surgery; * Missing key data.
Contact & Investigator
Guibin Qiao
PRINCIPAL INVESTIGATOR
Guangdong Provincial People's Hospital
Frequently Asked Questions
Who can join the NCT06771960 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Lung Cancer (NSCLC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06771960 currently recruiting?
Yes, NCT06771960 is actively recruiting participants. Contact the research team at guibinqiao@126.com for enrollment information.
Where is the NCT06771960 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT06771960 clinical trial?
NCT06771960 is sponsored by Guangdong Provincial People's Hospital. The principal investigator is Guibin Qiao at Guangdong Provincial People's Hospital. The trial plans to enroll 120 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.